AIM: AIM ImmunoTech, Inc. Short-Term Debt to Equity

This price chart for AIM ImmunoTech (AIM) on the GURU.Markets platform demonstrates a metric of 0.49. The business relies on the sale of immunomodulators supported by an optimized supply chain and warehouse network. The model operates via outsourced development and testing, eliminating plant-related expenditures. However, an excessive reliance on a single drug creates risks, necessitating the continuous attraction of third-party capital.

For AIM ImmunoTech, which ensures the seamless logistics of critical biopharmaceutical raw materials, a stable current loan-to-equity ratio on GURU.Markets confirms the company's ability to fund operating expenses without risking its stability. This indicator compares liabilities with a maturity of up to one year against equity, allowing investors to distinguish a temporary reallocation of liquidity from a systemic resource deficit.